Company profile
Home | Spirea: developing the next generation of antibody drug conjugates
Spirea, a biotech company spun out from the University of Cambridge, is committed to delivering the next generation of antibody drug conjugate (ADC) therapeutics to revolutionise cancer treatment and improve the lives of patients.
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
MA | Transaction MzUyMDA3MTc5MmFkaXF6a2N4 | Paper/PDF filed
Published 23 May 2026 22:44
RESOLUTIONS | Transaction WUYxSEM0SzNhZGlxemtjeA | Paper/PDF filed
Published 23 May 2026 22:40
Last confirmation statement made up date
Last accounts made up date
MA | Transaction MzQzNjUxNTgwOWFkaXF6a2N4 | Paper/PDF filed
Published 22 Sep 2024 06:00
RESOLUTIONS | Transaction QURCUUtaSk5hZGlxemtjeA | Paper/PDF filed
Published 22 Sep 2024 05:57
RESOLUTIONS | Transaction QURCUUtaSjdhZGlxemtjeA | Paper/PDF filed
Published 22 Sep 2024 05:56
RESOLUTIONS | Transaction QURCUUtaSkZhZGlxemtjeA | Paper/PDF filed
Published 22 Sep 2024 05:55
AP01 | Transaction MzQzNTU5OTIwMWFkaXF6a2N4
Published 13 Sep 2024 14:21
Company registered at Companies House
1 Nov 2025 to 30 Jun 2027
**The development of a first-in-class cancer therapeutic for difficult-to-treat metastatic Triple Negative Breast Cancer.** Spirea Ltd a cutting-edge spin-out from the University of Cambridge intents on revolutionizing cancer treatment with its pioneering Antibody-Drug Conjugate (ADC) for Triple Negative Breast Cancer (TNBC)---one of the most aggressive a...
1 Jan 2018 to 31 Mar 2019
Spirea is responding to challenges faced by the developers of next-generation cancer therapies, by applying its proprietary and proven core polymer platform technology. New classes of innovative pharmaceutical products are being developed to improve the effectiveness and safety of the potent drugs used to treat cancer, through precision medicine. In these...
